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The goal of this study was to determine whether bisphenol A (BPA) had adverse effects 23 indicative of cardiac toxicity. As part of the "Consortium Linking Academic and Regulatory 24
Insights on BPA Toxicity" (CLARITY-BPA), study dams and offspring were exposed by daily 25 gavage to five doses of BPA ranging from 2.5 to 25000 µg/kg/day, 0.05 or 0.5 µg/kg/day 17α-26 ethinyl-estradiol (EE) or 0.3% carboxymethylcellulose vehicle. Exposure-related effects were 27 analyzed in isolated hearts by quantitative morphometry and histopathology. No dose-related 28 changes in body weight were detected. Across all exposure groups including vehicle controls, 29 body weight of continuously dosed males was reduced compared to males dosed only until 30 PND21. Heart weight was increased only in females exposed to EE, and consistent alterations 31 in LV wall thickness were not observed. Exposure-related changes in collagen accumulation 32 were minor and limited to highest EE exposure groups with increased collagen accumulation in 33 PND21 males. Decreased collagen was observed in hearts of BPA or EE exposed females at 34 PND90 and PND180. In BPA or EE treated females cardiomyopathy incidence and severity was 35 significantly increased compared to control females at PND21 with myocardial degeneration 36 observed in both males and females at PND21 and PND90. 37
Introduction
comparative assessments of cardiac mass and left ventricular (LV) wall thickness, the extent of 115 cardiac fibrosis, and comparative histopathology of the study animal hearts in order to evaluate 116 extents of cardiotoxicity and inflammation induced by each exposure. 117 maintained ad libitum on a soy-and alfalfa-free diet (5K96 verified casein diet 10 IF, round 142 pellets, γ-irradiated; Purina Mills, Cat. 1810069) with Millipore-filtered water in glass water 143 bottles with silicone stoppers (#7721 clear, Plasticoid Co., Elkton, MD). Extracts of diet and 144 other study materials were analyzed for BPA, genistein, daidzein, zearalenone, and coumestrol 145 by liquid chromatography and mass spectrometry (25) . Each diet lot assayed contained less 146 BPA than the protocol-specified limit of 5 ppb (25), < 1 ppm genistein and daidzein, and < 0.5 147 ppm zearalenone and coumestrol. Drinking water, polysulfone cage leachates and bedding 148 were also analyzed and found to have BPA levels below the level of the average analytical 149 method blanks (24) . After the start of the CLARITY-BPA study, a hypothetical possibility that 150 study animals housed in animal rooms with animals dosed at 250,000 µg/kg/day BPA may have 151 resulted in unintended exposure to low levels of BPA, although there is no direct evidence for 152 contamination of the animals analyzed here (24, 26) . Post-analysis sample deidentification 153 revealed no PND90 animals were housed with the 250,000 µg/kg/day BPA animals, 17 of 155 154 PND21 (Supplemental Table 1 ), and 240 of 317 PND180 animals (Supplemental Table 2 ) 155 analyzed were housed in animal rooms with the high BPA exposure group. 156
Dams and pups were gavaged daily with vehicle (0.3% aqueous CMC, Sigma-Aldrich St. parturition (PND0). Litters with at least 6 animals were included in the analysis. On PND1 pups 167 were randomly culled from litters with more than 10 animals to achieve a maximum of 5 males 168 and 5 females per litter. Dosing of the F1 pups on PND1 by gavage was initiated after litters 169 were culled with daily dosing: 1) continuing until scheduled day of sacrifice at PND21, PND90 170 (±3 days) or 6 months of age ("continuous dose" groups); or 2) until PND21 with animals 171 housed without dosing until scheduled termination at PND90 (± 3 days) or 6 months of age 172 ("stop dose" groups). After weaning the same sex study animals were housed 2 per cage. At 173 PND21, PND 90 and 6 months terminal weights of the F1 animals were collected prior to 174 euthanasia, necropsy and tissue collection. 175
Tissue Collection, Preparation and Staining 176
At each of the three time points analyzed (PND21 (weaning), PND90, or 6 months), 177 animals were weighed, sacrificed and hearts were harvested with heart weights recorded at 178 NCTR. Each tissue specimen and all corresponding experimental endpoints (e.g. body and 179 heart weight measurements) were assigned a coded identification and all tissue preparation and 180 subsequent histopathologic analysis and scoring was done blinded to exposure group, exposure 181 duration or sex. Hearts were fixed for 24 hours in 10% formalin, post-fixed in fresh neutral 182 buffered formalin for an additional 24 hours, and then transferred to 70% ethanol for shipping. 183 described previously (17, 27) . Heart sections were stained with hematoxylin and eosin (H&E;
Richard-Allan, Kalamazoo, MI) using a standard protocol to examine tissue structure, 193 morphology and pathology. Left ventricular free wall area was measured and the average LV 194 free wall thickness was calculated from a single section at the level of the papillary muscle for 195 each study animal. Serial transverse sections at the level of the papillary muscle were also 196 stained with Picrosirius Red (Polysciences; Warrington, PA) to visualize total collagen (red) with 197 bright field illumination (28-31 images of each section were collected using a 1x and 10x objectives, with additional higher 207 magnification images collected using 20x and 40x objectives. Acquired images of picrosirius red 208 sections were captured in RGB file format and then converted to HSI file format using Image 209 Pro v4.5 (Media Cybernetics Silver Springs, MD). Images were confirmed as not containing 210 saturated pixels, and threshholded to background staining intensity. Total left ventricle (LV) area 211 and the total LV collagen staining were calculated with collagen staining reported as a percent 212 of LV area. Visual inspection of each slide was performed to qualitatively confirm the accuracy 213 of the computed levels of staining. From the H&E stained sections, 10x digital images were 214 acquired to examine gross and microscopic tissue structure and to measure LV free wall evenly spaced digital lines spanning the width of the left ventricular free wall were superimposed 218 onto the digital image from a single stained section at the level of the papillary muscle. The 219 average LV wall thickness was calculated as the mean length of those five lines relative to a 220 stage micrometer of known length. For morphometric data collection and analysis, all samples 221 including controls were comprehensively masked and were analyzed by a single observer blind 222 to exposure dose, exposure duration (stop vs. continuous) and sex (32). All digital results were 223 confirmed by direct microscopic observation. Pathologists), all pathology was assessed by the same investigator (RG). An independent 236 blinded pathology review was performed by a second investigator (JK) with any differences in 237 lesion grading reviewed and resolved by consensus of the research team. described elsewhere (24) . To avoid potential bias all primary data collection and analysis was 241 conducted blind to exposure and sex. All individual samples were received with a unique 242 numeric identifier assigned by the NCTR staff. Upon completion of primary data collection, 243 analysis and data quality review (SB and RG), the coded primary data were submitted to the 244 NTP Chemical Effects in Biological Systems (CEBS) data base administrator. Data was then 245 independently verified to contain all expected data for each endpoint, and upon approval of the 246 data Decoding Team all files were "locked" such that data could not be altered (read only 247 format). Upon archiving of data from all University-based research projects which shared a 248 common code, the data decoding information was supplied by NCTR to the CEBS Administrator 249 who performed quality assurance reviews of data integrity and the decoding information. Upon 250 approval by the CLARITY-BPA Decoding Team, the verified decoding information was supplied 251 to the PI (SMB). 252
Statistical Analysis 253
Detailed review and analysis of all the research plans included in the CLARITY-BPA 254 hypothesis driven studies followed NIEHS and NTP recommendation for evaluation of 10 255 animals per sex per group. Our previous analysis had found that n = 10 was a sufficient sample 256 size with enough statistical power to detect BPA exposure induced changes in the CD-1 mouse 257 heart for endpoints assessed here (17). Confound from litter effects are avoided by limiting 258 analysis at each time point to one animal of a given sex from each litter, with each sex being 259 considered separately. The statistical unit used was the litter for all analyses. A minimal level of 260 statistical significance for differences in values among or between groups was considered 261 p < .05. All statistical analyses for differences in values compared to control were made 262 independently for BPA and EE exposures and followed guidelines for low dose endocrine of the value) prior to statistical analysis. Data analysis was performed using Dunnett's multiple 265 comparison tests, one-way or two-way analysis of variance as indicated, and for pathology 266 severity scores, a rank order ANOVA Kruskal-Wallis H test with Dunn's multiple comparisons 267 tests were used. All data was analyzed using Excel (Microsoft; Redmond, WA) and GraphPad 268 Prism® v6 software (GraphPad; La Jolla, CA). 269
Morphometric Characterization: Body Weight 271
Analysis of variance showed there were no exposure related changes in body weight 272 detected at any time point analyzed (Table 1 ). An effect of exposure duration (stop dose vs. 
Morphometric Characterization: Heart Weight 283
At PND21 analysis of variance showed there was no main effect on absolute heart 284 weight [BPA male: F(5, 48) = 0.60, p = .70; female F(5, 52) = 1.08, p = .38: EE male F(2, 27) = 285 1.84, p = .10; female F(2, 26) = 0.68, p = 0.52] or relative heart weight indexed to body weight 286 [BPA male: F(5, 47) = 0.17, p = .97; female F(5, 51) = 0.87, p = .51: EE male F(2, 26) = 0.56, p 287 = .58; female F(2, 26) = 0.76, p = .48]. At PND90 absolute heart weight was influenced by 288 exposure in females continuously exposed to EE ( Table 2 ). Dunnett's multiple comparison tests 289 found at PND90 chronic the heart weight in females from the continuous 0.05 EE (p = .004, d = 290 2.03) and 0.5 EE (p = .0003, d = 2.12) exposure groups were significantly increased compared 291 to control. When heart weight at PND90 was indexed to body weight (Table 3) , a significant 292 effect was identified in both the 0.5 EE stop dose (p = .013, d = 1.48) and 0.5 EE continuous dose groups (p = .012, d = 1.27). At 6 months of age heart weight was significantly decreased in 294 stop dose 2.5 BPA females (p = .02, d = 1.38), and although the decrease in indexed heart 295 weight for the stop dose 2.5 BPA females failed to reach significance (p = .06), the effect size 296 remained large (d = 1.11). Heart weight (p = .001, d = 1.61) and indexed heart weight (p = 297 .0009, d = 1.88) were significantly increased in the 0.5 EE continuously dosed females. An 298 increase in the mean indexed heart weight for females in the continuously dosed 25 BPA group 299 was noted, but did not reach the criteria set for statistical significance, although the effect size 300 was again large (p = .053; d = 0.88). No other changes in absolute ( Table 2 ) or indexed heart 301 weight (Table 3) were identified. 302
LV Wall Thickness and Fibrosis 303
At PND 21 an analysis of variance showed there were no main effects of either BPA or 304 EE on LV wall thickness in either sex (Table 4) . At PND90 Dunnett's multiple comparison tests 305 indicated a significant decrease in LV wall thickness in the female stop dose 2.5 BPA group only 306 (p = .049, d = 1.19). In the 0.05 EE continuous dose group at 6 months a significant (p = .048, d 307 = 1.03) increase in LV wall thickness of females was identified (Table 4) . 308
Collagen accumulation was similar to control in each exposure group for both males and 309 females at PND21 (Table 5) with Dunnett's multiple comparison tests revealing a significant 310 increase (p = .027; d = 1.15) of LV collagen in male hearts from the 0.5 EE exposure group 311 (Table 5 ). For males at PND90 a two factor analysis of variance (exposure, duration) indicated a 312 significant effect of both exposure [F(1, 133) = 2.27, p = .033] and dose duration [F(1, 133) = 313 14.5, p = .0002] on amount of LV collagen that was not qualified by an interaction [F(7, 133) = 314 1.59, p = .14]. The mean percentage of LV collagen in continuously dosed control males (M = 315 3.38, SD = 1.18) was significantly increased (t(18) = 2.37, p = .029, d = 1.12) compared to stop 316 dose male control (M = 2.34, SD = 0.86). In females at PND90 LV collagen was not influenced 317 by exposure or dose duration. There was no discernable effect of dose duration on collagen accumulation in either sex at the 6 month time point, and Dunnett's multiple comparison tests 319 identified a significant (p = .006, d = 1.37) decrease of collagen in female hearts from the stop 320 dose 0.5 EE group (Table 5) . 321
Histopathology: Progressive Cardiomyopathy (PCM) 322
Cardiomyopathy-like lesions were frequently observed in the sections used for 323 characterization of LV wall thickness and fibrosis. As a result the incidence and severity of 324 myocardial lesions were characterized to investigate the hypothesis that there was a high 325 background level of cardiomyopathy in the hearts of control, and that exposure to EE or BPA 326 was increasing the incidence and severity of these lesions. Analysis of single transverse 327 sections of the heart for each animal identified lesions in 90% of males and 60% of control 328 females at PND21 (Table 6 ). In BPA or EE treated females at PND21 cardiomyopathy incidence 329 was increased compared to control females and a significant increase in severity was found for 330 2.5, 250, 25,000 µg/kg/day BPA and each EE group (Table 6 ). In a male exposed to 250 331 µg/kg/day BPA and a female from each of the two lowest BPA dose groups (2.5 and 25 332 µg/kg/day) a diffuse degeneration phenotype involving much of the myocardium was also 333 observed. Shown in Figure 1 are photomicrographs of H&E stained hearts sections from control 334 females showing representative lesions observed at PND21. Small regions of inflammatory cell 335 infiltrates indicative of the earliest stages of cardiomyopathy were frequently noted ( Fig. 1A  336 arrows). Areas of myocyte degeneration with extensive vacuolation of myocytes and lacking 337 evident fibrosis were also observed ( Fig. 1B) . Regions of highly disorganized myocyte 338 morphology, with evident myocyte degeneration, diffuse vacuolation, increased cellularity and 339 fibrosis consistent with a diagnosis of mid-stage PCM were readily apparent (Fig. 1C ). At this 340 age regions of focal fibrosis (late stage cardiomyopathy), often associated with the 341 endocardium, were also identified in the LV myocardium and the papillary muscle (Fig. 1D) .
was observed in 100% of control samples from both the stop dose and the continuous dose 344 arms of the study. Cardiomyopathy incidence at PND90 was essentially quantitative across all 345 dose groups with lesion severity similar for each exposure group. A diffuse degeneration 346 phenotype at PND90 (Table 7) Table 8 ) the incidence of 355 the inflammatory phenotype was greater in control males than in females, and lesions were 356 more often multifocal with a larger area of involvement ( Figure 2E ). In some cases myocyte 357 degeneration, necrosis, and inflammation with hemosiderin containing macrophages were 358 observed ( Fig. 2F; arrows) . Exposure related effects on cardiomyopathy above the background 359 observed in controls were not detectable at this later time point.
Discussion 361
The primary goal of the presented study was to determine the impact of BPA on cardiac 362 specific end points. These analyses are a part of a larger integrated multi-investigator effort 363 performed in parallel with the comprehensive GLP-compliant 2-year CLARITY-BPA chronic 364 exposure study investigating the toxicity of BPA (21, 24). The premise for analysis of these 365 cardiac endpoints was derived from accumulating evidence indicating that the heart is a target 366 for the effects of the endocrine disrupting chemical BPA (16-19, 37). While the heart of both 367 males and females express estrogen receptors (38), the impacts of ER activation by estradiol 368 and the disruptive actions of BPA in the heart are sex specifically regulated and often differ in 369 males and females (12, 13, (17) (18) (19) . At the onset of the study phenotypic changes related to 370 cardiac remodeling and changes in the collagen extracellular matrix were considered most likely 371 based on the established phenotypes observed in previous mouse studies investigating the 372 impacts of chronic BPA exposures (17-19). In general there was no evidence found here for 373 BPA grossly impacting cardiac endpoints related to hypertrophy in the NCTR-SD rat. Similar to 374 previous findings from the NCTR 90 day BPA toxicity study (25), heart weight was largely 375 unchanged by BPA exposures with increases found only in females exposed to EE. Consistent 376 alterations in LV wall thickness were also not observed. Exposure related changes in collagen 377 accumulation found here were minor and limited to highest EE exposures that resulted in 378 increased collagen accumulation in PND21 males and decreased collagen in hearts of BPA or 379 EE exposed females at PND90 and 6 months. There were higher baseline levels of ventricular 380 collagen in the NCTR-SD rat model compared to the mouse strains used in previous studies 381 (12, (17) (18) (19) . The relatively higher level of collagen observed in the rat heart is consistent with 382 known species specific differences in the proportions of myocytes and fibroblasts present in 383 murine and rat hearts (39). Whereas the majority of cells in the mouse heart are to size differences and differences in cardiac physiology and contractile function of mice and rats. For example, the heart rate in mouse is around 700 beats/min, whereas the rate in rat is 387 between 300-400 beats per min. The significant species differences in numerous parameters of 388 cardiac function, structure, cellular makeup and physiological response to pathology require 389 caution when extrapolating observations across different animal models and to human disease. 390
Exposure to BPA increases cardiac pathology: progressive cardiomyopathy 391
Rodent PCM is a common background lesion of unknown etiology that is suspected to 392 arise from a localized microvascular dysfunction. The resulting lesions phenotypically progress 393 from minor to extensive focal mononuclear cell infiltration, myocyte degeneration, and fibrosis. 394
The common occurrence of PCM lesions in some rat strains has presented challenges for 395 analyzing cardiotoxicity in regulatory toxicology studies of chemicals and pharmaceuticals due 396 to the difficulty of distinguishing background cardiomyopathy from exposure related effects of 397 chemical exposures (33, 34, 40-43). The Sprague-Dawley rat has been characterized as having 398 an especially high incidence of PCM compared to other rat strains and mice (43). 399
Due in part to the standardized design of most short and long-term toxicological studies, 400 PCM has not been well evaluated in young animals. Although anecdotal evidence suggests that 401 PCM has been observed in very young rats (44), to our knowledge the analysis presented here 402 is the first quantitative characterization of cardiomyopathy in rats at PND21. A remarkable 403 abundance of early PCM lesions were present in the hearts of most of the young prepubertal 404 study animals. Consistent with PCM found in adults, the lesion incidence and severity was 405 greater in control males than in females, and accordant with BPA have low dose cardiotoxic 406 effects, even at this early age one female in each of the two lowest BPA exposure groups (2.5 407 and 25 µg/kg/day) and a male in the 250 µg/kg/day group presented with a diffuse degeneration 408 phenotype in which evident pathology involved much of the myocardium was detected (40). 409
The significance of observing this pathology in these adolescent rats requires additional 410 study to define the nature and etiology because of the relatively limited number of study animals analyzed in each group and the infrequency of this most severe phenotype. The diffuse degeneration phenotype has been taken as indicative of cardiotoxicity (40), thus the findings of 413 this phenotype as early PND21 may suggest that the NCTR-SD strain is partially sensitive to 414 vascular perturbations of the EDC activities of BPA that result in this rare cardiovascular 415
pathology. An increased incidence of the diffuse degeneration myocardial pathology was also 416 observed at PND90 in both BPA and EE exposed male and female from the developmentally 417 exposed and the continuously exposed arms of the study. While the dose response 418 characteristic of this relatively rare phenotype should also be interpreted with caution, it is 419 notable that diffuse degeneration was observed most frequently in the lowest BPA exposure 420 groups (2.5 -250 µg/kg/day) of the continuously dosed animals. 421 While complicated by the high level of background pathology, the increases in PCM 422 observed in females at PND21 and the notable increase in myocardial degeneration at PND90 423 suggests that BPA and EE may impact cardiovascular functions resulting in an early onset of 424 vascular dysfunction and progression of cardiomyopathy. At the 6 month time point there is 425 notable absence of the diffuse degeneration phenotype. It is considered possible that the 426 absence of this phenotype at 6 months was the result of hypertrophic increases in heart size 427 that precluded lesion involvement reaching the grading criteria threshold of >81% LV area 428 involvement to be scored as diffuse degeneration (34-35). The histopathology findings at the 6 429 month time point (and to a lesser degree at PND21), as well as those for other endpoints, 430 however, should be interpreted cautiously as results may be confounded by the potential for low 431 level BPA contamination in many of the 6 month old animals including nearly all of the control 432 animals analyzed (24) . It is notable that the evidence for a low level of background BPA 433 exposure is only inferred from detection of BPA-glucuronide in control and 2.5 µg/kg/day BPA 434 groups from the NCTR BPA 90 day subchronic study (25). The low levels of background BPA 435 detected there were linked to housing of study animals with animals exposed to high for varying durations in animal rooms with animals dosed at 250,000 µg/kg/day BPA, it is 438 possible that an unintended exposure to low levels of BPA may have occurred. If a similar 439 unintended exposure did occur in the current study, BPA levels in some control animals may be 440 indistinguishable from the 2.5 µg/kg/day BPA exposure groups (26). 441
Effects of Exposure on Body Weight 442
Whereas studies using a variety of different developmental exposure paradigms in 443 differing rat and mouse strains have reported obesogenic and diabetogenic actions associated 444 with BPA exposure (reviewed in (45), there were no detectable impacts on body weight found in 445 the study cohort analyzed at any age or dose of BPA or EE. This finding is consistent with 446 numerous previous studies including our own that have consistently found evidence for sex 447 specific changes in cardiovascular and metabolic phenotypes of both rats and mice, but do not 448 detect evidence for BPA causing increases in adiposity and body weight (18, 19, 46-52). These 449 findings are also consistent with the majority of systematic reviews analyzing the strength of 450 evidence from human epidemiologic data which fail to support a causal link between BPA and 451 obesity or type two diabetes (53-55), although a recent systematic review and meta-analysis 452 has found evidence for a link between urinary BPA levels and risk of diabetes and increased 453 obesity (4). The inconsistent findings reported in both experimental animal studies and analyses 454 of human data evaluating the obesogenic potential of BPA is considered most likely due to 455 differences in experimental procedure, experimental design and analysis methods. 456
The observed significant differences in body weights between continuously dosed males 457 and males dosed only until weaning at PND21 indicate that there were sex specific impacts 458 related to post-weaning dosing procedures and/or the CMC vehicle. The sex-specific decreased 459 weight of males dosed daily with vehicle by gavage is consistent with previous studies showing rats are resistant to these effects of stress (56-58). Previous studies investigating impacts of 462 prenatal BPA exposure in the developing brain of the NCTR-SD rat have also found that 463 compared to offspring of untreated controls, gavage of pregnant dams with 0.3% CMC resulted 464 in altered estrogen receptor expression in the amygdala of their neonatal offspring (59). Those 465 findings indicated that some endpoints analyzed can be sensitive to either the vehicle and/or 466 maternal stress resulting from the dosing procedures. However, it is not possible to differentiate 467 whether these observed effects were related to different durations of exposure to CMC vehicle, 468 continuous daily restraint and gavage, or their combined effects. Recently chronic oral exposure 469 to CMC in drinking water of mice has been shown to disrupt normal metabolism by altering 470 mucus-microbial interactions that modify gut bacteria composition and metabolic function, 471 effects that caused increased intestinal inflammation, obesity and metabolic syndrome (60). 472
Based on that study, it would be expected that chronic exposure to vehicle would cause an 473 increase in weight. However, it is not possible to rule out the possibility that both exposure to 474 CMC and continuous daily restraint and gavage may be interacting and contributing to the body 475 weight differences observed in males. Determining whether manipulations related to daily 476 gavage or the test material vehicle is responsible for the observed confounding impacts on body 477 weight between continuously or developmentally dosed cohorts will require specific 478 experimental study to define the source(s) of differences in weight gain and possibly other 479 phenotypic impacts. 480
Study Limitations 481
Along with confounds related to the duration of dosing, there were additional constraints 482 related to conforming with the CLARITY-BPA consortium study design that did not allow 483 experimental manipulation or direct assessment of changes in cardiac function or 484 cardiovascular endpoints of interest (e.g. contractility and blood pressure) that may have limited 485 sensitivity to detect exposure related phenotypes. Overall previous experimental studies in and C57Bl6/n mice found compelling evidence for BPA to alter the collagen extracellular matrix of the heart and to potentially influence cardiac function and negatively impact heart health. The 488 pathology associated with the majority of these effects became most evident following adverse 489 cardiovascular events such as cardiac ischemia or myocardial infarction (17, 19) . It is well 490 accepted that experimental interventions resulting in increased β-adrenergic stress, ischemic 491 injury or genetic manipulations are often necessary to reveal cardiac fibrosis and hypertrophy or 492 phenotypes indicative of overt cardiac pathology in rodent models (61). Such manipulations 493
were not possible in this study and only post mortem tissues were available for analysis. The 494 inability to experimentally manipulate study animals is considered a limitation as the 495 morphometric endpoints we were able to analyze are relatively insensitive phenotypes. 496
Additional studies using procedures or models that develop CV disease phenotypes in rat could 497 be useful for clarification of BPA impacts on the heart. 498
Conclusions 499
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